Data / Form D filings / Morphoceuticals, Inc.
Morphoceuticals, Inc.: Form D filings
Morphoceuticals, Inc., a biotechnology company in Medford, MA, filed 2 Form D notices with the SEC between 2023 and 2024. The latest, on October 7, 2024, reports $3.5 million sold of a $5.5 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 200 Boston Avenue, Suite G-725, Medford, MA, 02155
- Phone
- (858) 603-2514
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1962989
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 7, 2024 | New notice | $5,500,000 | $3,500,000 | $2,000,000 | 1 | Sep 23, 2024 | sec.gov |
| Jan 23, 2023 | New notice | $9,820,000 | $9,820,000 | 3 | Jan 13, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Michael R. Hufford | Director | |
| Alexander R. Pickett | Director | |
| Justin R. Briggs | Director | |
| Tamim Hamad J.J Al-Thani | Director | |
| Rosemarie R. Hunziker | Director | |
| James Jenson | Executive Officer, Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Oct 7, 2024 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Morphoceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.